GNMLF saw its Momentum Indicator move above the 0 level on December 09, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator turned positive. In of the 36 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence Histogram (MACD) for GNMLF turned negative on November 26, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 25 similar instances when the indicator turned negative. In of the 25 cases the stock turned lower in the days that followed. This puts the odds of success at .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (57.958). P/E Ratio (9.470) is within average values for comparable stocks, (89.727). GNMLF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.037) settles around the average of (0.122) among similar stocks. P/S Ratio (0.790) is also within normal values, averaging (19.472).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GNMLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNMLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that GNMLF and AQST have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNMLF and AQST's prices will move in lockstep.
Ticker / NAME | Correlation To GNMLF | 1D Price Change % | ||
---|---|---|---|---|
GNMLF | 100% | N/A | ||
AQST - GNMLF | 21% Poorly correlated | -10.13% | ||
LVRLF - GNMLF | 20% Poorly correlated | -13.04% | ||
VEXTF - GNMLF | 20% Poorly correlated | N/A |